Literature DB >> 1478360

Bioprocess factors affecting glycoprotein oligosaccharide structure.

C F Goochee1.   

Abstract

The oligosaccharide structures of glycoproteins can have a profound effect on properties critical to the development of glycoprotein products for human therapeutic or diagnostic use, including clearance rate, antigenicity, specific activity, solubility, resistance to thermal inactivation, and resistance to protease attack. Therefore, it is important to understand how bioprocess factors influence oligosaccharide structure. In this presentation, I will summarize literature data concerning potential effects of bioprocess factors on glycoprotein oligosaccharide biosynthesis. These data are drawn from two recent detailed reviews published by our laboratory describing the effect of cell culture conditions on N-linked glycosylation (10) and the effects of other bioprocess factors on both N-linked and O-linked glycosylation (11).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1478360

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  5 in total

1.  Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation.

Authors:  C Kronman; B Velan; D Marcus; A Ordentlich; S Reuveny; A Shafferman
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

2.  Bovine acetylcholinesterase: cloning, expression and characterization.

Authors:  I Mendelson; C Kronman; N Ariel; A Shafferman; B Velan
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

3.  Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts.

Authors:  K Panneerselvam; H H Freeze
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

4.  Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by Mammalian cell systems.

Authors:  M Butler
Journal:  Cytotechnology       Date:  2006-06-09       Impact factor: 2.058

5.  Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy.

Authors:  Frank DeRosa; Lianne Smith; Yinghua Shen; Yan Huang; Jing Pan; Hongsheng Xie; Barak Yahalom; Michael W Heartlein
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.